Angiotensin-converting enzyme inhibitor-related angioedema: How to deal with it

Expert Opinion on Drug Safety

Volumn 5, Issue 5, 2006, Pages 643-649

  Beltrami, Laura ^a   Zingale, Lorenza C ^a   Carugo, Stefano ^a   Cicardi, Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Angiodema; Angiotensin II receptor blocker; Angiotensin converting enzyme inhibitor; Bradykinin

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BRADYKININ; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C1S INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ICATIBANT; OMAPATRILAT; SUBSTANCE P; DRUG DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT;

ACCURACY; ANAMNESIS; ANGIONEUROTIC EDEMA; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; COUGHING; DELAYED DIAGNOSIS; DIAGNOSTIC ERROR; DRUG MECHANISM; DRUG WITHDRAWAL; GENETIC SUSCEPTIBILITY; HEREDITY; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INCIDENCE; LARYNX EDEMA; MEDICAL DOCUMENTATION; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; REVIEW; CHEMICALLY INDUCED DISORDER; EXPERT WITNESS;

ANGIONEUROTIC EDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRADYKININ; EXPERT TESTIMONY; HUMANS;

EID: 33747455671     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.5.643     Document Type: Review

References (64)

1. ALDERMAN CP: Adverse effects of the angiotensin-converting enzyme inhibitors. Ann. Pharmacother. (1996) 30(1):55-61.
2. BROWN NJ, VAUGHAN DE: Angiotensin-converting enzyme inhibitors. Circulation (1998) 97(14):1411-1420.
3. VLEEMING W, VAN AMSTERDAM JG, STRICKER BH, DE WILDT DJ: ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf. (1998) 18(3):171-188.
4. BROWN NJ, SNOWDEN M, GRIFFIN MR: Recurrent angiotensin-converting enzyme inhibitor--associated angioedema. JAMA (1997) 278(3):232-233.
5. AGAH R, BANDI V, GUNTUPALLI KK: Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome. Int. Care Med. (1997) 23(7):793-796.
6. AGOSTONI A, CICARDI M, CUGNO M, ZINGALE LC, GIOFFRE D, NUSSBERGER J: Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology (1999) 44(1-2):21-25.
7. SABROE RA, BLACK AK: Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br. J. Dermatol. (1997) 136(2):153-158.
8. ORR KK, MYERS JR: Intermittent visceral edema induced by long-term enalapril administration. Ann. Pharmacother. (2004) 38(5):825-827.
9. MLYNAREK A, HAGR A, KOST K: Angiotensin-converting enzyme inhibitor-induced unilateral tongue angioedema. Otolaryngol. Head Neck Surg. (2003) 129(5):593-595.
10. SONDHI D, LIPPMANN M, MURALI G: Airway compromise due to angiotensin-converting enzyme inhibitor-induced angioedema: clinical experience at a large community teaching hospital. Chest (2004) 126(2):400-404.
11. AGOSTONI A, CICARDI M: Drug-induced angioedema without urticaria. Drug Saf. (2001) 24(8):599-606.
12. WARNER KK, VISCONTI JA, TSCHAMPEL MM: Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema. Ann. Pharmacother. (2000) 34(4):526-528.
13. KYRMIZAKIS DE, PAPADAKIS CE, FOUNTOULAKIS EJ, LIOLIOS AD, SKOULAS JG: Tongue angioedema after long-term use of ACE inhibitors. Am. J. Otolaryngol. (1998) 19(6):394-396.
14. CUGNO M, NUSSBERGER J, CICARDI M, AGOSTONI A: Bradykinin and the pathophysiology of angioedema. Int. Immunopharmacol. (2003) 3(3):311-317.
15. EBO DG, STEVENS WJ, BOSMANS JL: An adverse reaction to angiotensin-converting enzyme inhibitors in a patient with neglected C1 esterase inhibitor deficiency. J Allergy Clin. Immunol. (1997) 99(3):425-426.
16. SCHILLER PI, MESSMER SL, HAEFELI WE, SCHLIENGER RG, BIRCHER AJ: Angiotensin-converting enzyme inhibitor-induced angioedema: late onset, irregular course, and potential role of triggers. Allergy (1997) 52(4):432-435.
17. ISRAILI ZH, HALL WD: Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann. Intern. Med. (1992) 117(3):234-242.
18. ABDI R, DONG VM, LEE CJ, NTOSO KA: Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. Pharmacotherapy (2002) 22(9):1173-1175.
19. NUSSBERGER J, CUGNO M, AMSTUTZ C, CICARDI M, PELLACANI A, AGOSTONI A: Plasma bradykinin in angio-oedema. Lancet (1998) 351(9117):1693-1697.
20. SIGLER C, ANNIS K, COOPER K, HABER H, VAN DECARR S: Examination of baseline levels of carboxypeptidase N and complement components as potential predictors of angioedema associated with the use of an angiotensin-converting enzyme inhibitor. Arch. Dermatol. (1997) 133(8):972-975.
21. KIM KS, KUMAR S, SIMMONS WH, BROWN NJ: Inhibition of aminopeptidase P potentiates wheal response to bradykinin in angiotensin-converting enzyme inhibitor-treated humans. J. Pharmacol. Exp. Ther. (2000) 292(1):295-298.
22. LEFEBVRE J, MURPHEY LJ, HARTERT TV, JIAO SHAN R, SIMMONS WH, BROWN NJ: Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension (2002) 39(2 Pt 2):460-464.
23. ADAM A, CUGNO M, MOLINARO G, PEREZ M, LEPAGE Y, AGOSTONI A: Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet (2002) 359(9323):2088-2089.
24. BROWN NJ, BLAIS C, JR., GANDHI SK, ADAM A: ACE insertion/deletion genotype affects bradykinin metabolism. J. Cardiovasc. Pharmacol. (1998) 32(3):373-377.
25. MOLINARO G, CUGNO M, PEREZ M et al.: Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J. Pharmacol. Exp. Ther. (2002) 303(1):232-237.
26. DUAN QL, NIKPOOR B, DUBE MP et al.: A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am. J. Hum. Genet. (2005) 77(4):617-626.
27. NIKPOOR B, DUAN QL, ROULEAU GA: Acute adverse reactions associated with angiotensin-converting enzyme inhibitors: genetic factors and therapeutic implications. Expert Opin. Pharmacother. (2005) 6(11):1851-1856.
28. BAS M, HOFFMANN TK, BIER H, KOJDA G: Increased C-reactive protein in ACE-inhibitor-induced angioedema. Br. J. Clin. Pharmacol. (2005) 59(2):233-238.
29. CHIU AG, NEWKIRK KA, DAVIDSON BJ, BURNINGHAM AR, KROWIAK EJ, DEEB ZE: Angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter review and an algorithm for airway management. Ann. Otol. Rhinol. Laryngol. (2001) 110(9):834-840.
30. ISHOO E, SHAH UK, GRILLONE GA, STRAM JR, FULEIHAN NS: Predicting airway risk in angioedema: staging system based on presentation. Otolaryngol. Head Neck Surg. (1999) 121(3):263-268.
31. DEAN DE, SCHULTZ DL, POWERS RH: Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. J. Forensic Sci. (2001) 46(5):1239-1243.
32. JASON DR: Fatal angioedema associated with captopril. J. Forensic Sci. (1992) 37(5):1418-1421.
33. ULMER JL, GARVEY MJ: Fatal angioedema associated with lisinopril. Ann. Pharmacother. (1992) 26(10):1245-1246.
34. MULLINS RJ, SHANAHAN TM, DOBSON RT: Visceral angioedema related to treatment with an ACE inhibitor. Med. J. Aust. (1996) 165(6):319-321.
35. SCHMIDT TD, MCGRATH KM: Angiotensin-converting enzyme inhibitor angioedema of the intestine: a case report and review of the literature. Am. J. Med. Sci (2002) 324(2):106-108.
36. CICARDI M, ZINGALE LC, BERGAMASCHINI L, AGOSTONI A: Angioedema associated with angiotensin-converring enzyme inhibitor use: outcome after switching to a different treatment. Arch. Intern. Med. (2004) 164(8):910-913.
37. MESSERLI FH, NUSSBERGER J: Vasopeptidase inhibition and angio-oedema. Lancet (2000) 356(9230):608-609.
38. NIELSEN EW, GRAMSTAD S: Angioedema from angiotensin-converting enzyme (ACE) inhibitor treated with complement 1 (C1) inhibitor concentrate. Acta Anaesthesiol Scand. (2006) 50(1):120-122.
39. NO AUTHORS LISTED: Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. Prescrire Int. (2005) 14(79):180-186.
40. BROWN NJ, RAY WA, SNOWDEN M, GRIFFIN MR: Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin. Pharmacol. Ther. (1996) 60(1):8-13.
41. GAINER JV, NADEAU JH, RYDER D, BROWN NJ: Increased sensitivity to bradykinin among African Americans. J. Allergy Clin. Immunol. (1996) 98(2):283-287.
42. RAFII MS, KOENIG M, ZIAI WC: Orolingual angioedema associated with ACE inhibitor use after rtPA treatment of acute stroke. Neurology (2005) 65(12):1906.
43. HILL MD, LYE T, MOSS H et al.: Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology (2003) 60(9):1525-1527.
44. MOREAU ME, GARBACKI N, MOLINARO G, BROWN NJ, MARCEAU F, ADAM A: The kallikrein-kinin system: current and future pharmacological targets. J. Pharmacol. Sci. (2005) 99(1):6-38.
45. AGOSTONI A, CICARDI M: Contraindications to the use of ace inhibitors in patients with C1 esterase inhibitor deficiency. Am. J. Med. (1991) 90(2):278.
46. BERKUN Y, SHALIT M: Hereditary angioedema first apparent in the ninth decade during treatment with ACE inhibitor. Ann. Allergy Asthma Immunol. (2001) 87(2):138-139.
47. KLEINER GI, GICLAS P, STADTMAUER G, CUNNINGHAM-RUNDLES C: Unmasking of acquired autoimmune C1-inhibitor deficiency by an angiotensin-converting enzyme inhibitor. Ann. Allergy Asthma Immunol. (2001) 86(4):461-464.
48. LIN RY, CANNON AG, TEITEL AD: Pattern of hospitalizations for angioedema in New York between 1990 and 2003. Ann. Allergy Asthma Immunol. (2005) 95(2):159-166.
49. CICARDI M, CONCIATO L, AGOSTONI A: Angioedema due to angiotensin-converting enzyme inhibition: an association frequently unrecognized. Ann. Ital. Med. Int. (1997) 12(1):8-10.
50. ASSADI FK, WANG HE, LAWLESS S, MCKAY CP, HOPP L, FATTORI D: Angiotensin converting enzyme inhibitor-induced angioedema: a report of two cases. Pediatr. Nephrol. (1999) 13(9):917-919.
51. TABRIZCHI R: Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders. Drugs (2003) 63(20):2185-2202.
52. KOSTIS JB, PACKER M, BLACK HR, SCHMIEDER R, HENRY D, LEVY E: Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am. J. Hypertens. (2004) 17(2):103-111.
53. HOWES LG, TRAN D: Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema? Drug Saf. (2002) 25(2):73-76.
54. HERNANDEZ-HERNANDEZ R, SOSA-CANACHE B, VELASCO M, ARMAS-HERNANDEZ MJ, ARMAS-PADILLA MC, CAMMARATA R: Angiotensin II receptor antagonists role in arterial hypertension. J. Hum. Hypertens. (2002) 16(Suppl. 1):S93-S99.
55. LO KS: Angioedema associated with candesartan. Pharmacotherapy (2002) 22(9):1176-1179.
56. CAMPBELL DJ, KRUM H, ESLER MD: Losartan increases bradykinin levels in hypertensive humans. Circulation (2005) 111(3):315-20.
57. ACHARYA KR, STURROCK ED, RIORDAN JF, EHLERS MR: Ace revisited: a new target for structure-based drug design. Nat. Rev. Drug Discov. (2003) 2(11):891-902.
58. GINSBURG GS, KONSTANCE RP, ALLSBROOK JS, SCHULMAN KA: Implications of pharmacogenomics for drug development and clinical practice. Arch. Intern. Med. (2005) 165(20):2331-2336.
59. CLAYTON TA, LINDON JC, CLOAREC O: Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature (2006) 440(7087):1073-1077.
60. AEBERSOLD R: Constellations in a cellular universe. Nature (2003) 422(6928):115-116.
61. NICHOLSON JK, LINDON JC, HOLMES E: 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica (1999) 29(11):1181-1189.
62. NICHOLSON JK, CONNELLY J, LINDON JC, HOLMES E: Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. (2002) 1(2):153-161.
63. LINDON JC, HOLMES E, NICHOLSON JK: Metabonomics: systems biology in pharmaceutical research and development. Curr. Opin. Mol. Ther. (2004) 6(3):265-272.
64. TURNER AJ, HOOPER NM: The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol. Sci. (2002) 23(4):177-183.